{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transthyretin+Amyloidosis&page=2",
    "query": {
      "condition": "Transthyretin Amyloidosis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transthyretin+Amyloidosis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:02:19.608Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00630864",
      "title": "The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transthyretin-associated Amyloidosis With Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "Fx-1006A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2008-06",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2013-01-18",
      "last_synced_at": "2026-05-22T05:02:19.608Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00630864"
    },
    {
      "nct_id": "NCT05489549",
      "title": "Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Amyloidosis, Hereditary",
        "Amyloidosis Cardiac",
        "Amyloidosis, Familial",
        "Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy",
        "Transthyretin Gene Mutation"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 500,
      "start_date": "2022-11-21",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-05-22T05:02:19.608Z",
      "location_count": 3,
      "location_summary": "New York, New York • Cleveland, Ohio • Dallas, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05489549"
    },
    {
      "nct_id": "NCT02175004",
      "title": "Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "FAP",
        "Familial Amyloid Polyneuropathy",
        "TTR",
        "Transthyretin",
        "Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Inotersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2014-06-26",
      "completion_date": "2021-01-07",
      "has_results": true,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-05-22T05:02:19.608Z",
      "location_count": 9,
      "location_summary": "Orange, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02175004"
    },
    {
      "nct_id": "NCT07358078",
      "title": "DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transthyretin Amyloidosis With Cardiomyopathy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2026-01-09",
      "completion_date": "2030-10-23",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-22T05:02:19.608Z",
      "location_count": 4,
      "location_summary": "Naples, Florida • Boston, Massachusetts • New Brunswick, New Jersey + 1 more",
      "locations": [
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07358078"
    },
    {
      "nct_id": "NCT01981837",
      "title": "Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "TTR-mediated Amyloidosis"
      ],
      "interventions": [
        {
          "name": "ALN-TTRSC (revusiran) for subcutaneous administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 26,
      "start_date": "2013-12",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2023-03-20",
      "last_synced_at": "2026-05-22T05:02:19.608Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01981837"
    },
    {
      "nct_id": "NCT00628745",
      "title": "Transthyretin Amyloidosis Outcome Survey (THAOS)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transthyretin Gene Mutations",
        "Transthyretin Amyloidosis"
      ],
      "interventions": [
        {
          "name": "None. Observational Study.",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6718,
      "start_date": "2008-01-04",
      "completion_date": "2023-06-19",
      "has_results": true,
      "last_update_posted_date": "2024-11-22",
      "last_synced_at": "2026-05-22T05:02:19.608Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00628745"
    },
    {
      "nct_id": "NCT01617967",
      "title": "Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "TTR-mediated Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Patisiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 29,
      "start_date": "2012-05",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2024-04-19",
      "last_synced_at": "2026-05-22T05:02:19.608Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01617967"
    },
    {
      "nct_id": "NCT04418024",
      "title": "Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "AG10",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eidos Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-10-21",
      "completion_date": "2024-04-30",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-05-22T05:02:19.608Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04418024"
    },
    {
      "nct_id": "NCT06186167",
      "title": "Amyloidosis Incidence in High-Risk Cardiac Device Patients",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Amyloid",
        "Cardiac Amyloidosis",
        "Amyloidosis Cardiac",
        "Systemic Amyloidosis",
        "AL Amyloidosis",
        "Infiltrative Cardiomyopathy, Amyloid",
        "ATTR Amyloidosis Wild Type"
      ],
      "interventions": [
        {
          "name": "Chest Wall Fat Tissue Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Midwest Heart & Vascular Specialists",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-01-29",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-05-22T05:02:19.608Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06186167"
    },
    {
      "nct_id": "NCT05797857",
      "title": "Exercise Training in Transthyretin Cardiac Amyloidosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Amyloid Cardiomyopathy",
        "Transthyretin Cardiac Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Exercise Training",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "60 Years to 90 Years"
      },
      "enrollment_count": 40,
      "start_date": "2024-07-10",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-03-18",
      "last_synced_at": "2026-05-22T05:02:19.608Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05797857"
    }
  ]
}